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ABSTRACT
Introduction: Analysis of platelet function, acetylsalicylic acid (ASA) and clopidogrel resistance in patients 
with peripheral arterial disease (PAD) undergoing percutaneous transluminal angioplasty (PTA), the impact of 
procedure on this phenomenon, connection with diabetes, hypertension, smoking. 
Material and methods: The study included 72 patients, with a group of patients taking ASA on a permanent 
basis and a group of patients in whom treatment was implemented after the procedure. Patients were also 
divided according to the antiplatelet therapy applied, either double-therapy, or ASA monotherapy. Daily doses 
were 75 mg. Three methods were used for the evaluation of the platelet function: IVY bleeding time, cytometric 
evaluation of platelet surface antigen (CD62p and CD63) expression and hemostasis measurement by PFA-200®. 
Results: In the PFA-200 analysis, ASA resistance was found in 37.8% (64.7% were tobacco smokers) before 
surgery. Patients not taking ASA before, after PTA and first dose of ASA presented resistance in 63%. The first 
dose of clopidogrel after surgery was associated with resistance in 73.7%. Significant differences in the expression 
of CD62p and CD63 markers before and after PTA were observed. According to IVY method, aspirin resistance 
was found in 40% of patients permanently receiving ASA. 
Conclusions: Patients with PAD who undergo PTA are resistant to ASA in 40%, smoking is associated with 
this phenomenon. PTA increases the expression of CD62P and CD63, and thus the platelet activation, which 
is not adequately prevented by antiplatelet drugs at a dose of 75 mg. Dual antiplatelet therapy reduces the 
activation of thrombocytes more than the monotherapy of ASA.
Key words: platelet function, aspirin resistance, clopidogrel resistance, peripheral artery disease, 
percutaneous transluminal angioplasty
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Introduction
Endovascular treatment, due to its low invasiveness 
and good results, is commonly used in the treatment 
of patients with peripheral arterial disease (PAD), 
allowing to shorten hospitalization and recovery time. 
Percutaneous transluminal angioplasty (PTA), apart 
from the fact that it is associated with an increase in the 
activity of platelets, carries the risk of complications, 
including thrombosis. The prophylaxis of these com-
plications currently includes antiplatelet drugs ― most 
often acetylsalicylic acid (ASA) and clopidogrel. ASA is 
the secondary prophylaxis after PTA and the primary 
antithrombotic prevention in patients diagnosed with 
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symptomatic atherosclerosis of the lower extremities. 
Its use at a dose of 75–150 mg/day in patients with 
intermittent claudication significantly reduces the rates 
of strokes, myocardial infarctions and deaths caused by 
cardiovascular diseases. This dose of ASA was found to 
be as effective as higher daily doses [1]. In randomized 
trials [2, 3], there was also no correlation between the 
amount of ASA used and the achievement of antiplatelet 
effect. The use of high doses appears to be unjustified 
and is related with a higher risk of gastrointestinal 
bleeding [4–6]. ASA also improves vessel patency after 
revascularization [7]. Dual antiplatelet therapy (ASA 
and clopidogrel) is implemented i.a. in patients who 
underwent stent implantation into peripheral arteries 
[7, 8]. Despite the use of such therapy, adverse events, 
including stent thrombosis, are still observed [2, 7, 
9, 10]. In patients with PAD, there is a tendency to 
increased platelet activity, which may be resistant to 
the antiplatelet effect of ASA [11, 12]. The term aspirin 
resistance was first used in the early 1990s [13]. Aspirin 
resistance is defined either in terms of clinical symptoms 
(a thromboembolic event during drug use) or on the 
basis of laboratory tests determining the aggregating 
effect of platelets [14]. According to Patrono [15], the 
term aspirin resistance can be applied to clinical con-
ditions or laboratory measurements, e.g. the inability 
of aspirin to: protect the patient from thromboembolic 
complications, prolong bleeding time, block throm-
boxane synthesis, or produce an antiplatelet effect 
found in one or more in vitro tests. Aspirin resistance 
is also defined by the term high on-treatment platelet 
reactivity (HTPR) [16] or high residual platelet reac-
tivity (HRPR) during aspirin treatment [17]. In current 
reports, HRPR is recognized in 27.7% of respondents 
[17]. The concept of aspirin poor responsiveness (APR) 
is also used [18]. As for the laboratory determination 
of resistance, it is possible to assess the aggregation 
response of thrombocytes to arachidinate, adrenaline 
or collagen [14, 19, 20]. Another issue in antiplatelet 
therapy is resistance to clopidogrel, an antagonist of the 
P2Y12 receptor. According to studies [21], resistance 
to clopidogrel at a loading dose of 600 mg was found 
in 1 in 5 patients. However, in the reports from 2016 
[22, 23] in the Chinese population of patients after 
ischemic stroke, taking clopidogrel at a dose of 75 mg/ 
/day, using the aggregometry method, drug resistance 
was found respectively in 38.88% and 36% of them 
(light transmission aggregometry — LTA). According 
to Spiliopoulos et al., the prevalence of resistance to 
aspirin and clopidogrel in patients undergoing end-
ovascular interventions due to symptomatic PAD is 
approximately 50% [16]. The aim of this study was 
to assess the occurrence of resistance to antiplatelet 
drugs (acetylsalicylic acid and clopidogrel) in patients 
undergoing angioplasty, to determine the impact of the 
procedure on the development of aspirin resistance, to 
determine whether there is a relationship between the 
occurrence of drug resistance and diabetes, hyperten-
sion or smoking and the assessment of platelet activity 
based on the expression of platelet surface glycopro-
teins on the day after the procedure depending on the 
antiplatelet therapy used (monotherapy with ASA or 
ASA in combination with clopidogrel). 
Material and methods
The study was conducted in the Department of Vascu-
lar Surgery and Angiology of the Medical University of 
Lublin from December 2011 to December 2015. Cyto-
metric tests and analysis of thrombocyte function using 
the INNOVANCE PFA-200® analyzer were performed 
in the Laboratory of Flow Cytometry and Hemostasis 
at the Department of Hematooncology and Bone Mar-
row Transplantation at the Medical University of Lublin. 
The study included a total of 72 patients (Table 1) 
with PAD, aged 44 to 89, including 20 women and 52 
men. Each patient underwent PTA. The patients were 
qualified for angiography and endovascular treatment 
based on the clinical condition assessed on the basis of 
the Fontaine scale — grades IIB, III, IV. 
After initial angiography, balloon angioplasty was 
performed in 34 (47.2%) patients. One or more stents 
were implanted in 38 (52.8%) patients. The endovas-
cular procedure was performed on iliac arteries in 
26 patients, in 46 patients on femoral, popliteal or 
tibio-fibular arteries (Table 2). During each procedure 
a bolus of unfractionated heparin i.v. (2500–5000 IU) 
was injected.
A group of 45 patients who were taking ASA at 
a dose of 75 mg daily for at least 2 weeks before the 
planned surgery was selected. The remaining 27 pa-
tients had not received any antiplatelet medication for 
at least 7 days prior to PTA. After returning from the 
operating room, patients who underwent balloon an-
gioplasty (n = 34) received 75 mg of ASA, while those 
after stent implantation (n = 38) received 75 mg of 
ASA and 75 mg of clopidogrel (Table 3). 
In studied patients, on the day of the procedure 
before its performance and on the first day after the 
procedure, the following additional tests were per-
formed to assess platelet function: measurement of the 
occlusion time using the PFA-200 analyzer, cytometric 
analysis, bleeding time (BT) measured according to 
the Ivy method. The material for laboratory tests was 
fasting whole blood collected from the cephalic vein 
using a 20Gx Needle (Sarstedt S-Monovette Nümbre-
cht, Germany). Blood was collected in 3 polystyrene 
tubes (Sarstedt S-Monovette) containing 3.2% sodium 
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citrate in the proportion 1:9. Then, within 2 hours of 
collection, the occlusion time was analyzed using the 
PFA-200 and the expression of platelet glycoproteins 
with the use of a cytometric analyzer. 
Description of the methods of assessing  
platelet function used in the study 
The PFA-200® system is used to measure the primary 
hemostasis process. It allows for a quick assessment of 
platelet function based on the analysis of non-clotted 
whole blood collected in citrate. With its use, it is pos-
sible to diagnose congenital and acquired platelet de-
fects, as well as to evaluate drug-induced dysfunctions. 
Using the flow cytometry method, the activation of 
platelets and their function can be tested. For this pur-
pose, monoclonal antibodies that are directed against 
platelet surface antigens are used. Specific phenotypic 
changes in platelet glycoproteins can be determined by 
the use of fluorescent-labeled antibodies. Changes in 
the expression of CD62p (P-selectin) and CD63 (GP53 
glycoprotein) surface proteins were found in numerous 
studies. These two molecules are the most expressive 
markers of platelet activation [24, 25]. In our study, 
the measurement of bleeding time (BT) using the Ivy 
method was also used. It is the only way to assess he-
mostasis in vivo. The bleeding time is the time between 
the incision is made and bleeding stops [26]. It proves 
the ability of platelets to form a blood clot at the site of 
skin damage. Standardized Surgicutt® Adult skin incision 
lancet were used to measure bleeding time. The correct 
bleeding time for the Ivy method was assumed to be 6 
minutes [26–29]. The group of patients with bleeding 
time up to 360 seconds was defined as resistant to the 
antiplatelet effect of used drugs. 
Table 3. Pharmacological treatment in the perioperative period 
Antiplatelet drugs administered  
permanently before the procedure 
Number of  
patients
Antiplatelet drugs administrated at the day  
of the procedure, after its performance 
Number of  
patients
ASA 45 ASA 34
Clopidogrel 0 ASA + clopidogrel 38
Without antiplatelet drug 27 Without antiplatelet drug 0
Table 2. Characteristics of the performed endovascular procedures 
Number of patients who underwent balloon angioplasty 34 (47.2%)
Number of patients with stent implantation 38 (52.8%)
Number of procedures performed within iliac arteries 26 (36.1%)
Number of procedures performed within femoral, popliteal arteries and tibial-peroneal trunk 46 (63.9%)
Table 1. Clinical characteristics of the study population (n = 72) 
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Statistical methods 
Statistical analyzes were performed using the Statistica 9. 
The following methods were used: descriptive statistics 
(mean, median, minimum, maximum, standard devia-
tion, standard error of the mean); percentage analysis; 
tests of significance of differences — Mann-Whitney 
U test, sign test for dependent groups, Kruskal-Wallis 
test, Chi2 test; correlation analysis using the r-Pearson 
coefficient. The critical level of statistical significance 
was p < 0.05.
Results 
Resistance to the antiplatelet effect of aspirin 
measured with PFA-200 
The mean closure time (CT) measured with the Col/ 
/EPI test cartridges in the group of 45 patients receiving 
ASA on a permanent basis before surgery was 185.6 
seconds. After the procedure, the CT was shortened 
to an average of 170.5 s. This means that PTA, despite 
the daily use of ASA, is associated with a decreased 
response to the antiplatelet effect of the drug. In the 
group of 45 patients taking ASA, drug resistance was 
found in 37.8% of patients using the PFA-200 device 
(n = 17). In the same group of patients, after PTA, 
a reduced response to the effects of ASA was observed 
in a greater number of patients ― 46.7% (n = 21). In the 
studied group of ASA-resistant patients (n = 17), a high 
percentage of smokers (64.7%) and a low percentage 
of diabetics (35.3%) were found. The coexistence of 
arterial hypertension is not associated with the aspirin 
resistance (53% in the study group are diagnosed with 
this disease). In the group of 27 patients not taking the 
drug before the procedure, CT was measured on the 
first day of the procedure and aspirin resistance was 
found in 63% of them (n = 17). ASA at a dose of 75 mg 
administrated only after PTA is associated with a very 
high percentage of resistance. In the entire group of 72 
patients participating in the study, a reduced response 
to the effects of ASA, measured with the PFA-200, was 
found in 38 patients (52.8%). Therefore, regardless of 
whether the patients were taking ASA in the period 
before the procedure or they received the drug only 
after the procedure, an increase in resistance caused by 
PTA was found. When analyzing the whole study popu-
lation, a low percentage of diabetic patients was found 
in the drug-resistant group (n = 38). However, the 
coexistence of arterial hypertension and smoking was 
not related with the occurrence of this phenomenon. 
Resistance to the antiplatelet effect  
of clopidogrel measured with PFA-200
In a group of 38 patients in whom at least one stent 
was implanted, after administration of a dose of 75 mg 
clopidogrel immediately after surgery, a study was per-
formed with P2Y test cartridges. The patients had not 
taken the drug before. The drug resistance was found 
in 28 subjects (73.7%). This means that clopidogrel is 
less effective at this dose on the first day of its use. In 
the group of patients resistant to the first dose of 75 mg 
clopidogrel after stenting (n = 28), a higher percentage 
of smokers (60.7%) compared to non-smokers was 
observed. Patients with diabetes accounted for only 
28.6% of the group. The number of patients with hy-
pertension was the same as the number without. In the 
group of patients responding to clopidogrel (n = 10), 
a very low percentage of patients with diabetes (20%) 
was found. 
Expression of P-selectin 
In the group of patient taking ASA (n = 45) before PTA, 
the mean percentage of platelet activation measured 
with CD61/CD62P was 0.36, after the procedure, it 
was increased to 0.51. In the group of patients who 
did not take the drug before PTA (n = 27), the mean 
percent activation for CD61/CD62P cells was 0.25 and 
after surgery it increased to 0.74. The mean percentage 
of CD61/CD62P cell activation in patients after surgery 
(PTA with stent implantation) and dual antiplatelet 
therapy (n = 38) was 0.79. Before the procedure, this 
value was lower, averaging 0.33. Similarly, in patients 
after PTA without stent implantation and using a single 
antiplatelet therapy with ASA (n = 34) before proce-
dure, the value was lower than after (0.5) and was 0.37. 
In the entire group of patients with PAD (n = 72), the 
mean value of the parameter before the procedure 
was 0.32. The surgery, despite the used antiplatelet 
therapy, increased the activation of platelets to the 
mean value of 0.60. 
Expression of CD63 
Both in treated with ASA (n = 45) and ASA-free group 
(n = 27), the mean percentage of postoperative CD61/ 
/CD63 cell activity was higher than before (2.0 and 
1.17 and 1.39 and 1.15). This means an increase in the 
expression of the platelet activation marker (CD63) 
as a result of the PTA, despite the use of antiplatelet 
therapy after the procedure (in this case, regardless of 
whether the patients received ASA or ASA and clopi-
dogrel). Mean percentage of CD61/CD63 cell activity 
in postoperative period (PTA with stent implantation) 
and dual antiplatelet therapy (n = 38), as in patients 
(with PTA without stent implantation) and with ASA 
monotherapy (n = 34) as in the entire group of 72 
patients before the procedure was lower (1.57; 1.76; 
1.50, respectively) compared to post-procedural testing 
(2.05; 1.95; 1.80, respectively). The surgery, despite 
the antiplatelet therapy used, increases the activation 
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of platelets, measured with the use of CD61/CD63 
antibodies. 
Results of tests with assessment of bleeding 
time using the Ivy method 
The mean bleeding time (BT) measured using the Ivy 
method for the group permanently receiving ASA be-
fore surgery (n = 45) was 444 seconds. In the group 
of patients taking ASA at a dose of 75 mg a day (n = 
= 45), the bleeding time was normal in 18 patients, so 
in 40% of patients, the drug did not prolong bleeding 
time, and thus this group can be considered as with low 
sensitivity to the antiplatelet effect of ASA. In the group 
of patients who underwent stenting and receiving dual 
antiplatelet therapy (n = 38), on the first day of PTA, 
the bleeding time was normal in 13 patients (34.2%). In 
the group of patients who were treated with ASA 75 mg 
monotherapy (n = 34), the correct bleeding time was 
detected in 14 patients, which means 41.2% of drug 
resistance. The mean bleeding time was 408 seconds, 
which was shorter than in the dual antiplatelet therapy 
group (477.2 seconds). The use of dual antiplatelet ther-
apy results in a better antiplatelet effect as it increases 
bleeding time. In the group of ASA-resistant patients 
tested before the PTA procedure (n = 17), the correct 
bleeding time was also found before the procedure in 
5 of them, which is 29.4%. In the assessment before 
the angioplasty procedure, in the group of 45 patients 
receiving ASA permanently, there were 5 patients re-
sistant to the drug effect according to the two methods 
used in the study, which constitutes 11.1%. 
Discussion 
Numerous studies report that the resistance to the 
antiplatelet effect of acetylsalicylic acid may affect from 
5 to 60% of patients, this discrepancy depending on 
the studied population and methods used to evaluate 
it. According to some researchers, this percentage is 
even as high as 83% [1, 30–34]. One of the first pub-
lished reports on ASA resistance concerned its use in 
secondary prevention in patients with stroke — the 
above problem was found (using PFA-100) in 30–40% 
of patients [35]. In our study, with the use of the 
PFA-200 device, in a group of patients with PAD who 
took ASA on a permanent basis, drug resistance was 
found in a very similar percentage of patients — 37.8%. 
In the study of Linneman et al. [36], the change in 
response to the effect of ASA was tested over time in 
patients with PAD, using e.g. PFA analyzer. It has been 
found that in a significant number of patients, resistance 
to aspirin changes over time during treatment. It may 
be related to inconsistency in the methodology, incom-
patibility in the applied therapy, insufficient response to 
the selected dose of the drug or interactions with other 
drugs. In addition, platelet activity may change as the 
disease progresses. In this study, resistance to aspirin 
and platelet function were assessed only before the PTA 
procedure and in the first 24 hours after. This resulted 
from the planned evaluation of the drug resistance in 
the periprocedural period, the aim of which was to 
determine the impact of the procedure itself on the 
resistance and to assess the effectiveness of the doses 
of drugs used at that time. For this reason, the possible 
long-term dynamics of the response to antiplatelet 
drugs was not assessed. There were also observations 
that resistance to ASA progressed over time, regard-
less of the dose taken [37, 38]. In a study [39] where 
platelet function was measured several times over 12 
months of ASA use, response to the drug did not matter 
in determining long-term outcomes. In a meta-analysis 
assessing the effect of aspirin in prevention of throm-
boembolic complications, it was found that most of the 
studies performed used different methods of testing 
the laboratory activity of thrombocytes. Furthermore, 
despite the same methods, different cut-off points 
were used. It has been found that patients presenting 
aspirin resistance in biochemical tests also tend to be 
“clinically resistant” with a significantly higher risk of 
cardiovascular complications. People with a significant 
activation of platelets, despite the use of aspirin, show 
an almost four times higher total risk of a cardiovascular 
event [40]. 
In our research, it was observed that in the group 
of patients identified as aspirin-resistant before PTA 
(n = 17), 64% were tobacco smokers. However, 
in the group of aspirin-resistant patients (n = 38) 
selected from the entire study population (n = 72), 
nicotinism coexisted in 55% of them. This confirms 
previous researches that smoking tobacco can cause 
drug resistance. It can be concluded that the increased 
pro-aggregation activity of thrombocytes in smokers, as 
in other studies [41, 42], is the main factor determining 
the higher incidence of cardiovascular diseases despite 
the systematic use of the drug in prophylactic doses. In 
this study, both in the group of patients diagnosed as 
aspirin-resistant before the procedure (n = 17) and in 
the entire study group on the day after the procedure 
(n = 38), the percentage of patients with coexisting 
diabetes was nearly 40%, which does not coincide 
with the majority of previous studies, suggesting that 
a patient with diabetes is more often drug-insensitive. 
In diabetic patients, increased activity with a tendency 
to aggregation of platelets was found, and therefore 
a higher incidence of thromboembolic complications 
[43, 44]. However, according to some reports, diabetes 
does not affect the development of aspirin resistance 
and the percentage of this phenomenon among dia-
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betics is comparable to the group of patients without 
diagnosed diabetes [45, 46]. The clinical importance 
of biochemically determined aspirin resistance in the 
development of cardiovascular complications has been 
confirmed [13, 35]. For example, in the study of Gum 
et al. [33], it was suggested that about 10% of recurrent 
adverse vascular events may be caused by resistance 
to ASA. This confirms that such prognosis of clinical 
complications, correlating with laboratory resistance, 
is extremely important for defining the scope and na-
ture of resistance to antiplatelet drugs. Several studies 
have shown that patients with a decreased response 
to clopidogrel, measured in vitro using platelet function 
analyzers have a significantly increased risk of early stent 
thrombosis after percutaneous coronary angioplasty 
(PTCA) compared to patients with sufficient platelet 
function blocking [23]. Most of the studies on clopi-
dogrel resistance concerned the study of platelet func-
tion after a loading dose of 300 mg [47]. In our study, 
the antiplatelet effect of clopidogrel was tested with the 
first day of 75 mg dose. Such a study was designed to 
determine whether the applied dose is effective in this 
group of patients, or whether it is worth considering 
using a higher dose on the day of surgery. Resistance to 
clopidogrel also varied between investigators, but there 
was a correlation between laboratory resistance and 
cardiovascular adverse events. In the work of Metzky 
et al. [48], patients with myocardial infarction treated 
with angioplasty were monitored for the effect of clopi-
dogrel by the optical aggregation method, using ADP 
as an agonist. This allowed identification of a group of 
25% of patients resistant to the drug effect, and thus 
more at risk of recurrent cardiovascular events. The 
only characteristic of this group was the high percent-
age of tobacco smokers. In the study by Cuisset et al. 
on patients with acute coronary syndrome, there was 
described a higher frequency of periprocedural infarc-
tions in the group with a poor laboratory response to 
clopidogrel [49, 50]. So far, a small number of studies 
have been published assessing the antiplatelet efficacy 
of clopidogrel tested with the PFA-200 analyzer [51]. 
In our study, the tests were made on the first day of 
the procedure, so the assessment concerns one dose 
of 75 mg, confirming its very low effectiveness. Only 
10 patients had a correct response to the drug, which 
is 26.3% in the study group. The remaining patients 
(73.7%) can be diagnosed with reduced responsiveness 
to the antiplatelet effect of clopidogrel. In this study, 
the cytometric test and the Ivy method for the bleeding 
time were used to compare dual antiplatelet therapy 
with ASA monotherapy. P-selectin and CD63 are es-
tablished markers of thrombocyte activity measured 
by flow cytometry [52, 53]. According to E. McKenzie 
et al. [53], a significant decrease in the expression of 
these glycoproteins was described only after a high 
dose of ASA, which suggests the use of higher doses 
in patients treated endovascularly. The expression 
of P-selectin and GP53 was examined in all patients 
included in the study (n = 72) both before and after 
surgery. It was found that P-selecting expression was 
higher in patients who underwent stenting and received 
two antiplatelet drugs compared to those who had only 
balloon angioplasty and received ASA. 
As for CD63 expression, its level after PTA was 
comparable in both groups, regardless of the therapy 
used. Thus, stenting causes a greater activation of plate-
lets, assessed by this marker, than balloon angioplasty 
itself. The inhibitory effect of ASA and clopidogrel on 
the expression of these markers of platelet activity 
(mainly P-selectin) described so far is weaker than the 
effect of endovascular treatment causing the increase in 
expression. The assessment of the bleeding time using 
the Ivy method was found to be normal in 13 patients 
in the group that received dual antiplatelet therapy after 
stent implantation (n = 38). This means that 34.2% of 
the study group was not responsive to the effects of 
these drugs. On the other hand, in the group of patients 
after balloon angioplasty and receiving 75 mg of acetyl-
salicylic acid (n = 34), 41.2% were resistant after the 
procedure. Moreover, the mean bleeding time is also 
higher in patients treated with ASA and clopidogrel (477 
vs 408 seconds). The above results, despite the lack 
of statistical significance, allow us to observe that dual 
antiplatelet therapy is associated with better inhibition 
of thrombocyte function resulting in prolonged bleeding 
time. It is worth paying attention to the fact that the 
implementation of such therapy is more effective even 
in relation to patients who have had a stent implanted, 
which is also associated with a higher activation of 
platelets than after balloon angioplasty only. 
In this study, an increase in P-selectin expression 
after surgery, and thus in platelet activation, was found, 
assessed on a group of patients receiving ASA perma-
nently (n = 45). In the preoperative ASA group (n = 
= 27), a significant increase in the mean percentage of 
activation of CD61/62p antibodies was observed. This 
difference is greater than in patients using ASA before 
the procedure, so it can be concluded that the treating 
patient with aspirin before the procedure results in 
a lower activation of platelets, and thus a lower risk of 
developing thrombotic complications in the first days 
after PTA. Some studies do not describe that aspirin 
impacts the level of P-selectin expression [54]. Accord-
ing to studies [53] with the use of flow cytometry, in 
which several markers of platelet activation were used, 
a decrease in P-selectin expression was found already 
at the dose of 1.0 g of ASA. On the other hand, after 
a higher dose of 4.0 g, a statistically significant decrease 
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in the expression of CD63 antibodies, while after 
a small dose, a slight increase in the expression of CD63. 
After a week of using ASA at a dose of 81 mg/day, Val-
des et al. [55] found a decrease in the concentration 
of soluble P-selectin (sP-selectin) in the blood. The 
studies carried out on a group of healthy people who 
were administered ASA in a dose of 81 mg showed that 
there was a decrease in the expression of thrombocyte 
surface receptors, including P-selectin [56]. In this 
study, it was shown that the percentage of antibody 
activation before PTA was lower than after PTA, which 
means that in patients with PAD, angioplasty causes an 
increased activation of platelets, which is insufficiently 
prevented by the drugs used. The search for an effective 
antiplatelet therapy for patients with PAD is extremely 
important, also because these patients clearly have 
an increased risk of myocardial infarction or ischemic 
stroke [11]. In this study, in the group of patients 
permanently receiving ASA in a daily dose of 75 mg 
(n = 45), the level of aspirin resistance confirmed by 
two methods — PFA-200 and the Ivy method was 
found in 5 patients, which makes 11% of this group. 
The above group of patients can be described as “true” 
aspirin-resistant, because they present the features 
of resistance in both biochemical and in the in vivo 
test. Moreover, studies evaluating aspirin resistance in 
relation to the development of thromboembolic com-
plications in patients undergoing antiplatelet therapy 
estimate the prevalence of resistance at a very similar 
level. In the analysis of Gum et al. [33], the importance 
of aspirin resistance in thrombotic complications was 
estimated at 10%. Similar results were presented by 
Saunders et al. [57], where in a group of 80 patients with 
PAD using the PFA-100, persistent aspirin resistance 
was detected in 9.9% of patients.
Despite many recent studies, it has not been 
possible to clearly define which group of patients 
should be diagnosed for aspirin resistance. Though the 
number of available, relatively simple and quick tests 
for determining the activity of platelets is increasing, 
the cost of the equipment and the tests themselves 
will not allow such extensive diagnostics in the near 
future. A definition of a patient resistant to aspirin and 
clopidogrel should be created, which will also enable 
the development of new or specification of already 
used tests independent of additional factors modifying 
the action of these drugs.
Conclusions
Based on the own research presented above, it was 
found that among patients with peripheral arterial 
disease treated with endovascular methods, the level 
of laboratory aspirin resistance is about 40%. An addi-
tional factor that increases the resistance to antiplatelet 
drugs is tobacco smoking. Previous PTA procedure 
results in increased resistance to antiplatelet drugs. 
As a result of PTA, the expression of P-selectin and 
CD63 increases, and thus the activation of platelets 
also increases, which is insufficiently prevented by the 
antiplatelet drugs used in the periprocedural period: 
ASA and clopidogrel. Dual antiplatelet therapy reduces 
the activation of platelets to a greater extent compared 
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